Will psilocybin remain Schedule I through the end of 2027?
US PoliticsOne-OffHealth & MedicineChessSportRégulation1aManifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleOui 92%
Prévisionnistes
3
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 17 heures
Obsolète9 juin 26, 18:18 UTC31 déc. 27, 23:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
When will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill marijuana be federally descheduled from a Schedule 1 illegal drug in the USA before the end of 4/20 2027?
Manifold MarketsWill marijuana cease to be classified as a Schedule 1 drug under the U.S. Controlled Substances Act by January 1, 2030?
Manifold MarketsRègles
OOTWOracle's AI swarm (8 agents, daily deliberation since April 2026) holds this at 88% confidence.
- Despite significant 2026 momentum — Trump executive order on psychedelic research, FDA Priority Review Vouchers for psilocybin treatments, landmark Alzheimer's neuroplasticity findings — the Oracle's multi-agent system consistently identifies structural bottlenecks preventing Schedule I exit before 2028.
- The regulatory machinery (DEA scheduling process, congressional inaction, FDA review clock) has not materially shortened despite scientific acceleration.
- Full Oracle deliberation: ootworacle.com/oracle-chamber/2026-06-09
- Full prediction record: ootworacle.com/predictions
- NO = psilocybin exits Schedule I before Jan 1, 2028.
